Mariana Canelas-Pais

Mariana Canelas-Pais

Auto-generated profile, based on publicly available information

Mariana Canelas-Pais

Department of Community Medicine, Information and Decision in Health, Faculty of Medicine, University of Porto

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2023 in Human Reproduction
Verified
Journal Article
Closed access
PDF file
FRFilipa Rafael
Filipa Rafael
MRMaria Dias Rodrigues
Maria Dias Rodrigues
JBJose Bellver
Jose Bellver
MCMariana Canelas-Pais
Mariana Canelas-Pais
NGNicolas Garrido
Nicolas Garrido
SSSamuel Santos-Ribeiro
Samuel Santos-Ribeiro
For a woman with infertility and overweight/obesity, can infertility treatment be postponed to first promote weight loss? Advice regarding a delay in IVF treatment to optimize female weight should consider female age, particularly in women over 38 years for whom only substantial weight loss in a short period of time (3 months) seems to provide any benefit. Body weight excess and advanced age are both common findings in infertile patients, creating the dilemma of whether to promote weight loss first or proceed to fertility treatment immediately. Despite their known impact on fertility, studies assessing the combined effect of female age and BMI on cumulative live birth rates (CLBRs) are still scarce and conflicting. We performed a multicentre retrospective cohort study including 14 213 patients undergoing their first IVF/ICSI cycle with autologous oocytes and subsequent embryo transfers, between January 2013 and February 2018 in 18 centres of a multinational private fertility clinic. BMI was subdivided into the following subgroups: underweight (<18.5 kg/m2), normal weight (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2), and obesity (≥30.0 kg/m2). The primary outcome was CLBR. The secondary outcome was time to pregnancy. To assess the influence of female age and BMI on CLBR, two multivariable regression models were developed with BMI being added in the models as either an ordinal categorical variable (Model 1) or a continuous variable (Model 2) using the best-fitting fractional polynomials. CLBR was estimated over 1-year periods (Model 1) and shorter timeframes of 3 months (Model 2). We then compared the predicted CLBRs according to BMI and age. When compared to normal weight, CLBRs were lower in women who were overweight (adjusted odds ratio (aOR) 0.86, 95% CI 0.77–0.96) and obese (aOR 0.74, 95% CI 0.62–0.87). A reduction of BMI within 1 year, from obesity to overweight or overweight to normal weight would be potentially beneficial up to 35 years old, while only a substantial reduction (i.e. from obesity to normal BMI) would be potentially beneficial in women aged 36–38 years. Above 38 years of age, even considerable weight loss did not compensate for the effect of age over a 1-year span but may be beneficial in shorter time frames. In a timeframe of 3 months, there is a potential benefit in CLBR if there is a loss of 1 kg/m2 in BMI for women up to 33.25 years and 2 kg/m2 in women aged 33.50–35.50 years. Older women would require more challenging weight loss to achieve clinical benefit, specifically 3 kg/m2 in women aged 35.75–37.25 years old, 4 kg/m2 in women aged 37.50–39.00 years old, and 5 kg/m2 or more in women over 39.25 years old. This study is limited by its retrospective design and lower number of women in the extreme BMI categories. The actual effect of individual weight loss on patient outcomes was also not evaluated, as this was a retrospective interpatient comparison to estimate the combined effect of weight loss and ageing in a fixed period on CLBR. Our findings suggest that there is potential benefit in weight loss strategies within 1 year prior to ART, particularly in women under 35 years with BMI ≥25 kg/m2. For those over 35 years of age, weight loss should be considerable or occur in a shorter timeframe to avoid the negative effect of advancing female age on CLBR. A tailored approach for weight loss, according to age, might be the best course of action. No specific funding was obtained for this study. All authors have no conflicts to declare. N/A.

24 May 2023 in Atherosclerosis
Verified
Journal Article
Open access
CGCristina Gavina
Cristina Gavina
FAFrancisco Araújo
Francisco Araújo
CTCarla Teixeira
Carla Teixeira
JRJorge A. Ruivo
Jorge A. Ruivo
ACAna Luísa Corte-Real
Ana Luísa Corte-Real
Tiago Taveira-GomesTiago Taveira-Gomes
Tiago Taveira-Gomes
Cardiovascular (CV) diseases show clear differences in clinical manifestation and treatment outcomes between men and women. To reduce sex disparities in achieving lipid-lowering therapy (LLT) goals, a sex-focused assessment is essential and more studies are needed to bring new evidence to clinicians. This study aims to assess the role of sex in attaining low-density lipoprotein cholesterol (LDL-C) goals, after correction for age, CV risk category, LLT intensity, and presence of mental health disorder and social deprivation. A retrospective cohort analysis of patients aged 40-85, followed in 1 hospital and 14 primary care centers in Portugal, using electronic health records from 1/1/2012 to 31/12/2020, was performed. The analysis considered an episode-based design, where exposure consists of any time when LLT was started or intensity changed. The likelihood of reaching the LDL-C goal according to contemporary ESC/EAS guidelines was modeled using multivariate Cox regression. LDL-C goal achievement at 180 days was defined as the outcome. The analysis was repeated at 30-day follow-up intervals up to 360 days, and also stratified by CV risk category. We identified 40,032 exposure episodes (LLT initiation or intensity change) in 30,323 distinct patients. Male sex, older age, lower CV risk and increasing LLT intensity were associated with improved LDL-C control. Women were 22% less likely to reach the LDL-C goal than men (HR = 0.78, 95% CI:0.73, 0.82) independently of covariates. Women have a lower likelihood of attaining LDL-C goals than men after adjustment for LLT intensity, age, CV risk category, presence of mental health disorder and social deprivation. This finding underscores the need for further investigation and tailoring of LLT management strategies in women.

9 May 2023 in Endoscopy
Verified
Journal Article
Closed access
PDF file
ARAndreia Rei
Andreia Rei
RORaquel Ortigão
Raquel Ortigão
MPMariana Pais
Mariana Pais
LALuís Pedro Afonso
Luís Pedro Afonso
PPPedro Pimentel-Nunes
Pedro Pimentel-Nunes
DLDiogo Libanio
Diogo Libanio
Background Surveillance after gastric endoscopic submucosal dissection (ESD) is recommended for all patients owing to the persistent risk of metachronous gastric lesions (MGLs). We developed and validated a prediction score to estimate MGL risk after ESD for early neoplastic gastric lesions, to define an individualized and cost-saving approach. Methods Clinical predictors and a risk score were derived from meta-analysis data. A retrospective, single-center, cohort study including patients with ≥ 3 years of standardized surveillance after ESD was conducted for score validation. Predictive accuracy of the score by the area under the receiver operating characteristic curve (AUC) was assessed and cumulative probabilities of MGL were estimated. Results The risk score (0–9 points) included six clinical predictors (scored 0–3): positive family history of gastric cancer, older age, male sex, corpus intestinal metaplasia, synchronous gastric lesions, and persistent Helicobacter pylori infection (FAMISH). The study population included 263 patients. The MGL rate was 16 %. The score diagnostic accuracy for predicting MGL at 3 years’ follow-up, measured by the AUC, was 0.704 (95 %CI 0.603–0.806). At 3 years and a cutoff < 2, the score achieved maximal sensitivity and negative predictive value; 15 % of patients could be assigned to a low-risk group, in which the progression to MGL was significantly lower than for the high-risk group (P = 0.04). Conclusion The FAMISH score might be a useful tool to accurately identify patients with low-to-intermediate risk for MGL at 3 years of follow-up who could have surveillance intervals extended to reduce the burden of care.

6 November 2023 in Clinical Cardiology
Verified
Journal Article
Open access
CGCristina Gavina
Cristina Gavina
DSDaniel Seabra‐Carvalho
Daniel Seabra‐Carvalho
CACarlos Aguiar
Carlos Aguiar
AAAnastassia Anastassopoulou
Anastassia Anastassopoulou
CTCarla Teixeira
Carla Teixeira
Tiago Taveira-GomesTiago Taveira-Gomes
Tiago Taveira-Gomes
Aim: This study aims to characterize sociodemographic and clinical characteristics, use of lipid‐lowering therapies (LLTs), and low‐density lipoprotein cholesterol (LDL‐C) control in a population with increased cardiovascular (CV) risk.Methods: A cross‐sectional observational study that uses electronic health records of patients from one hospital and across 14 primary care health centers in the North of Portugal, spanning from 2000 to 2020 (index date). Patients presented at least (i) 1 year of clinical data before inclusion, (ii) one primary care appointment 3 years before the index date, and (iii) sufficient data for CV risk classification. Patients were divided into three cohorts: high CV risk; atherosclerotic cardiovascular disease (ASCVD) risk equivalents without established ASCVD; evidence of ASCVD. CV risk and LDL‐C control were defined by the 2019 and 2016 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) dyslipidemia guidelines.Results: A total of 51 609 patients were included, with 23 457 patients classified as high CV risk, 19 864 with ASCVD equivalents, and 8288 with evidence of ASCVD. LDL‐C control with 2016 ESC/EAS guidelines was 32%, 10%, and 18% for each group, respectively. Considering the ESC/EAS 2019 guidelines control level was even lower: 7%, 3%, and 7% for the same cohorts, respectively. Patients without any LLT prescribed ranged from 37% in the high CV risk group to 15% in patients with evidence of ASCVD.Conclusion: We found that LDL‐C control was very low in patients at higher risk of CV events. An alarming gap between guidelines on dyslipidemia management and clinical implementation persists, even in those at very high risk or with established ASCVD.

5 April 2024 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
CGCristina Gavina
Cristina Gavina
DCDaniel Seabra Carvalho
Daniel Seabra Carvalho
MAMarta Afonso-Silva
Marta Afonso-Silva
DADaniela Brandão Abreu
Daniela Brandão Abreu
MCMariana Canelas-Pais
Mariana Canelas-Pais
FAFrancisco Araújo
Francisco Araújo

29 August 2024 in medRxiv
Verified
Preprint
Open access
PDF file
MPMarta Pineda-Moncusí
Marta Pineda-Moncusí
ARAlexandros Rekkas
Alexandros Rekkas
ÁPÁlvaro Martínez Pérez
Álvaro Martínez Pérez
ALAngela Leis
Angela Leis
CGCarlos Lopez Gomez
Carlos Lopez Gomez
TBTheresa Burkard
Theresa Burkard
Importance Drug production not meeting the demand leaves affected patients in a vulnerable position. Objective To describe incidence and prevalence of medicines with suggested shortages in at least one European country Design We performed a descriptive cohort study between 2010 in a network of databases which have mapped their data to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). Setting Setting included primary care, secondary care, and various disease registries whose previously collected data was leveraged. Participants We included all patients with at least 365 days of history on the database. Exposures We investigated all medicines with a suggested shortage in at least one European country for more than 365 days (n=18). Furthermore, we assessed their alternatives as well (n=39). Main outcomes and measures We estimated annual incidence rates and period prevalence of all medicines with suggested shortages and their alternatives. A drop in incidence or prevalence of more than 33% after the shortage announce by the European Medicines Agency was considered confirmation of a shortage. Results Among 41 databases from Europe and the United States, we observed shortages according to incidence for 12 drugs and shortages according to prevalence for 4 drugs. The drugs varenicline, cetrorelix, and amoxicillin plus clavulanate were in shortage in the most countries. Conclusion and relevance We compiled and analysed data of annual incidence and prevalence of 57 medicines among 41 databases in Europe and the United States. We detected shortages of several drugs and suggest monitoring and stewardship for drug availability.